Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Mar 4;151(9):612-622.
doi: 10.1161/CIRCULATIONAHA.124.071153. Epub 2025 Feb 5.

Stepwise Provisional Versus Systematic Dual-Stent Strategies for Treatment of True Left Main Coronary Bifurcation Lesions

Affiliations
Randomized Controlled Trial

Stepwise Provisional Versus Systematic Dual-Stent Strategies for Treatment of True Left Main Coronary Bifurcation Lesions

Sandeep Arunothayaraj et al. Circulation. .

Abstract

Background: The optimal coronary stenting technique for true left main bifurcation lesions is uncertain. EBC MAIN (European Bifurcation Club Left Main Trial) aimed to evaluate clinical outcomes of a stepwise provisional strategy compared with a systematic dual-stent approach.

Methods: EBC MAIN was a randomized, investigator-initiated, open-label, multicenter, parallel-group trial conducted across 35 hospitals in 11 European countries. A total of 467 participants undergoing percutaneous coronary intervention for unprotected true left main bifurcation lesions were randomly assigned to the stepwise provisional strategy (n=230) or an upfront dual-stent approach (n=237). The mean (SD) age was 71 (10) years and 23% of participants were women. The primary end point was a composite of major adverse cardiac events, defined as all-cause mortality, all myocardial infarction, or clinically driven target lesion revascularization. Events were adjudicated by an independent clinical events committee and all analyses were by the intention-to-treat principle.

Results: At 3 years, the primary end point occurred in 54 of 230 (23.5%) stepwise provisional and 70 of 237 (29.5%) dual-stent patients (hazard ratio, 0.75 [95% CI, 0.53-1.07]; P=0.11). There was no significant difference in all-cause mortality (10.0% versus 13.1%) or myocardial infarction (12.2% versus 11.0%). However, target lesion revascularization was significantly lower in the stepwise provisional group (8.3% versus 15.6%; hazard ratio, 0.50 [95% CI, 0.29-0.86]; P=0.013). In this population, the mean side vessel diameter by quantitative angiography was 2.9 mm, and median side vessel lesion length was 5 mm. Significant interactions were identified between the assigned bifurcation strategy and both side vessel diameter and lesion length with respect to the primary outcome (P=0.009 and P=0.005, respectively), with smaller vessels (<3.25 mm diameter) and shorter lesions (<10 mm length) favoring the provisional approach.

Conclusions: In a European population with true left main stem bifurcation coronary disease requiring intervention, there was no difference in major adverse cardiovascular events between stepwise provisional and systematic dual-stent strategies at 3 years. Target lesion revascularization was significantly less frequent with the stepwise provisional approach, which should be the default strategy for noncomplex left main bifurcation coronary intervention.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02497014.

Keywords: angiography; percutaneous coronary intervention; stents.

PubMed Disclaimer

Conflict of interest statement

Dr Hildick-Smith reports serving as a proctor or advisor to Boston Scientific, Abbott, Medtronic, Terumo, Edwards, Occlutech, Gore, and Cardiovascular European Research Center. Dr Chieffo reports serving as a consultant for Abiomed, Biosensor, and Magenta, and receiving speaker fees from Abbott Vascular, Abiomed, Boston Scientific, and Cardinal Health. Dr Lefèvre reports lecturing for Abbott Proctoring, Edwards Proctoring, Boston Scientific, and Terumo Proctoring. Dr Morice reports serving as chief executive officer for the Cardiovascular European Research Center. Dr Pan reports lecture fees from Abbott and Boston Scientific. Dr Lassen reports lecturing and honoraria for Medtronic, Boston Scientific, and Terumo. Dr Banning reports an institutional grant from Boston Scientific and lecture fees from Boston Scientific, Abbott, and Medtronic. Dr Darremont reports lecture fees from Boston Scientific and Edwards. Dr Stankovic reports lecture fees from Medtronic, Boston Scientific, Abbott, and Terumo. The other authors report no conflicts of interest.

Publication types

Associated data